AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26639027 — intervention group
Group type: EXPERIMENTAL
Intervention: Delefilcon A (DF)
Number of subjects: 76
Study 24002584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent suction curettage
Number of subjects: 22
Study 24002584 — intervention group
Group type: COMPARATOR
Intervention: Curettage only
Number of subjects: 22
Study 23939405 — intervention group
Group type: EXPERIMENTAL
Intervention: Body vibration
Number of subjects: 23
Study 23939405 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control)
Number of subjects: 23
Study 19293172 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (4 month, randomised, placebo controlled trial)
Number of subjects: 130
Study 19293172 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 month, randomised, placebo controlled trial)
Number of subjects: 130
Study 17515173 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (flexible dosage)
Number of subjects: 37
Study 17515173 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (varying dosage)
Number of subjects: 37
Study 17515173 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 37
Study 15466324 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drainage
Number of subjects: 7
Study 15466324 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment
Number of subjects: 7
Study 11357303 — intervention group
Group type: EXPERIMENTAL
Intervention: Adehl (colforsin daropate hydrochloride) infusion (0.5 microgram.kg‐1.min‐1 for 6 hours)
Number of subjects: 26
Study 11357303 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Adehl treatment)
Number of subjects: 26
Study 9483471 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air hyperventilation
Number of subjects: 0
Study 9483471 — intervention group
Group type: COMPARATOR
Intervention: 5% CO2 breathing
Number of subjects: 0
Study 9483471 — intervention group
Group type: COMPARATOR
Intervention: 7% CO2 breathing
Number of subjects: 0
Study 9483471 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder patients (general)
Number of subjects: 0
Study 7509259 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (0.3 and 1 mg.kg-1)
Number of subjects: 12
Study 7509259 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (1 mg.kg-1 x h-1)
Number of subjects: 12
Study 7509259 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (highest dose)
Number of subjects: 12
Study 7509259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3177072 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy manipulation (alcohol beverage information)
Number of subjects: 79
Study 3177072 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention demanding tasks
Number of subjects: 79
Study 3177072 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol doses (0.0; 0.4; 0.6 g/kg)
Number of subjects: 79
Study 31099727 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytosterol Supplementation
Number of subjects: 0
Study 31099727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28271073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (first-line therapy)
Number of subjects: 177
Study 28271073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (all patients)
Number of subjects: 177
Study 26354521 — intervention group
Group type: EXPERIMENTAL
Intervention: mDCF (docetaxel 40 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1, 5FU 1000 mg/m2/d days 1 and 2, cisplatin 40 mg/m2 day 3)
Number of subjects: 56
Study 26354521 — intervention group
Group type: COMPARATOR
Intervention: EOX (epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, capecitabine 1250 mg/m2/d days 1-21)
Number of subjects: 56
Study 26354521 — intervention group
Group type: EXPERIMENTAL
Intervention: mDCF
Number of subjects: 56
Study 26354521 — intervention group
Group type: COMPARATOR
Intervention: EOX
Number of subjects: 56
Study 23357834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 86 mg
Number of subjects: 24
Study 23357834 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR 86 mg
Number of subjects: 24
Study 21276280 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 6 mg/d
Number of subjects: 30
Study 21276280 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 12 mg/d
Number of subjects: 30
Study 21276280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19246457 — intervention group
Group type: EXPERIMENTAL
Intervention: Acustimulation (n=101)
Number of subjects: 200
Study 19246457 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n=99)
Number of subjects: 200
Study 17210732 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg of morphine (MS)
Number of subjects: 60
Study 17210732 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLCB)
Number of subjects: 60
Study 15233702 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tegaserod treatment
Number of subjects: 500
Study 15233702 — intervention group
Group type: COMPARATOR
Intervention: Intermittent treatment
Number of subjects: 500
Study 15233702 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of treatment
Number of subjects: 500
Study 11046209 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ketamine
Number of subjects: 66
Study 11046209 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg midazolam
Number of subjects: 66
Study 11046209 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg ketamine
Number of subjects: 66
Study 11046209 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg/kg ketamine
Number of subjects: 66
Study 9504815 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional protein map of amniotic fluid proteins using IPG/SDS‐PAGE technique
Number of subjects: 0
Study 7828457 — intervention group
Group type: EXPERIMENTAL
Intervention: amikacin (AK) 15 mg/kg/day q.d. (n = 10)
Number of subjects: 22
Study 7828457 — intervention group
Group type: COMPARATOR
Intervention: amikacin (AK) b.i.d. (n = 12)
Number of subjects: 22
Study 7828457 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 healthy neonates)
Number of subjects: 22
Study 2875593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 2 mg
Number of subjects: 60
Study 2875593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 60
Study 2875593 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 60
Study 2875593 — intervention group
Group type: COMPARATOR
Intervention: Lormetazepam
Number of subjects: 60
Study 29645359 — intervention group
Group type: COMPARATOR
Intervention: Fatty Fish (FF)
Number of subjects: 79
Study 29645359 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina Sativa Oil (CSO)
Number of subjects: 79
Study 29645359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean Fish (LF)
Number of subjects: 79
Study 29645359 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study 26454186 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT) intervention, n=104
Number of subjects: 205
Study 26454186 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) control, n=101
Number of subjects: 205
Study 24272416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Training (PRT)
Number of subjects: 39
Study 24272416 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 39
Study 22415082 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 22
Study 22415082 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22
Study 20110289 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hepatic perfusion (IHP) with melphalan
Number of subjects: 99
Study 20110289 — intervention group
Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 99
Study 18803728 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient fortified cooked lunch meals
Number of subjects: 181
Study 18803728 — intervention group
Group type: COMPARATOR
Intervention: Unfortified cooked lunch meals
Number of subjects: 181
Study 15855695 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal androgen-DHEAS
Number of subjects: 57
Study 12651674 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.3 mg. kg(‐1). min(‐1))
Number of subjects: 30
Study 12651674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11062382 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg QD flutamide
Number of subjects: 440
Study 11062382 — intervention group
Group type: COMPARATOR
Intervention: 250 mg q8h flutamide
Number of subjects: 440
Study 8960395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine (100 ng/min)
Number of subjects: 14
Study 8960395 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 14
Study 1436563 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhydrate nefopam
Number of subjects: 54
Study 1436563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 3781500 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient mental health services
Number of subjects: 4254
Study 3781500 — intervention group
Group type: EXPERIMENTAL
Intervention: Any provider for mental health care
Number of subjects: 4254
Study 3781500 — intervention group
Group type: EXPERIMENTAL
Intervention: General medical providers
Number of subjects: 4254
Study 3781500 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual outpatient mental health expenses
Number of subjects: 4254
Study 29937265 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring Element Systems (SES)
Number of subjects: 29
Study 29937265 — intervention group
Group type: COMPARATOR
Intervention: Conventional Systems (CS)
Number of subjects: 29
Study 27310989 — intervention group
Group type: EXPERIMENTAL
Intervention: OLV with adjustable ventilation parameters (OLV-AP)
Number of subjects: 30
Study 27310989 — intervention group
Group type: COMPARATOR
Intervention: OLV with preset ventilation parameters (OLV-PP)
Number of subjects: 30
Study 23471544 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD treatment
Number of subjects: 150
Study 22961516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg intravenous)
Number of subjects: 80
Study 22961516 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 21677124 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (≥1200 mg calcium)
Number of subjects: 29
Study 21677124 — intervention group
Group type: COMPARATOR
Intervention: LOW (≤500 mg calcium)
Number of subjects: 29
Study 18826631 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer patients
Number of subjects: 200
Study 18826631 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer patients post-tumor excision
Number of subjects: 200
Study 18826631 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal breast cancer patients with previous hysterectomy
Number of subjects: 200
Study 18826631 — intervention group
Group type: COMPARATOR
Intervention: Controls (matched for age, menopausal and hysterectomy status)
Number of subjects: 200
Study 16054823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine-sufentanil infusion (Group SR, n=31)
Number of subjects: 62
Study 16054823 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine infusion (Group R, n=31)
Number of subjects: 62
Study 11252549 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz-containing triple therapy
Number of subjects: 0
Study 11252549 — intervention group
Group type: COMPARATOR
Intervention: indinavir-containing triple therapy
Number of subjects: 0
Study 9628275 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg once daily for 8 weeks
Number of subjects: 15
Study 9628275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9628275 — intervention group
Group type: COMPARATOR
Intervention: Troglitazone and Placebo
Number of subjects: 15
Study 7882656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (0.15% F) for home use every second month
Number of subjects: 206
Study 7882656 — intervention group
Group type: COMPARATOR
Intervention: Supervised fluoride rinsing with 0.2% sodium fluoride and supervised toothbrushings
Number of subjects: 206
Study 3337652 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative breathing exercises supervised by a physical therapist
Number of subjects: 153
Study 3337652 — intervention group
Group type: COMPARATOR
Intervention: No breathing exercises (Control group)
Number of subjects: 153
Study 1957991 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with Olea europaea extracts
Number of subjects: 37
Study 1957991 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (control group)
Number of subjects: 37
Study 14816 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (200 mg daily for five weeks)
Number of subjects: 16
Study 30814109 — intervention group
Group type: EXPERIMENTAL
Intervention: lapatinib at T0
Number of subjects: 429
Study 30814109 — intervention group
Group type: EXPERIMENTAL
Intervention: lapatinib at T1
Number of subjects: 429
Study 30814109 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab at T1
Number of subjects: 429
Study 30814109 — intervention group
Group type: EXPERIMENTAL
Intervention: lapatinib+trastuzumab at T1
Number of subjects: 429
Study 30814109 — intervention group
Group type: EXPERIMENTAL
Intervention: ct-miR-140-5p (part of trastuzumab signature)
Number of subjects: 429
Study 27862477 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven model for reaction prediction
Number of subjects: 0
Study 27862477 — intervention group
Group type: COMPARATOR
Intervention: Rule-based expert system
Number of subjects: 0
Study 25703475 — intervention group
Group type: EXPERIMENTAL
Intervention: Transepithelial CXL with Ricrolin TE
Number of subjects: 61
Study 25703475 — intervention group
Group type: COMPARATOR
Intervention: Epi-off CXL with isotonic riboflavin
Number of subjects: 61
Study 23957727 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented posterolateral lumbar fusion with spondylolisthesis reduction
Number of subjects: 72
Study 23957727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study 25426896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated oil (2 mL daily for 1 week)
Number of subjects: 18
Study 25426896 — intervention group
Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 18
Study 18036682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic pole walking (NW)
Number of subjects: 48
Study 18036682 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking
Number of subjects: 48
Study 17260365 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin 3,436 IU subcutaneously twice daily
Number of subjects: 29
Study 17260365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15726328 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrasive arthroplasty
Number of subjects: 30
Study 15726328 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteal arthroplasty
Number of subjects: 30
Study 15726328 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 30
Study 11694152 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen use alone
Number of subjects: 25665
Study 11694152 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone/progestin use
Number of subjects: 25665
Study 11694152 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT use (any type)
Number of subjects: 25665
Study 11694152 — intervention group
Group type: COMPARATOR
Intervention: No HRT use
Number of subjects: 25665
Study 9109726 — intervention group
Group type: EXPERIMENTAL
Intervention: buccal bioadhesive slow‐release tablet containing miconazole nitrate
Number of subjects: 36
Study 9109726 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 8197766 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate prophylactic radiotherapy (DXT group)
Number of subjects: 2800
Study 8197766 — intervention group
Group type: COMPARATOR
Intervention: Control (WP group)
Number of subjects: 2800
Study 3296794 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief stop smoking advice by physicians
Number of subjects: 258
Study 3296794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 258
Study 31340534 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of CurcuWIN® (50 mg of curcuminoids)
Number of subjects: 63
Study 31340534 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of CurcuWIN® (200 mg of curcuminoids)
Number of subjects: 63
Study 31340534 — intervention group
Group type: COMPARATOR
Intervention: Corn starch placebo (PLA)
Number of subjects: 63
Study 28857237 — intervention group
Group type: EXPERIMENTAL
Intervention: eSAID (26-item questionnaire)
Number of subjects: 51
Study 26208075 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based oral health education program (experimental group)
Number of subjects: 240
Study 26208075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in the program)
Number of subjects: 240
Study 24130433 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 46
Study 24130433 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 46
Study 21357988 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length graduated compression stockings (GCS) in CLOTS Trial 1
Number of subjects: 5632
Study 21357988 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-length graduated compression stockings (GCS) in CLOTS Trial 2
Number of subjects: 5632
Study 21357988 — intervention group
Group type: COMPARATOR
Intervention: No graduated compression stockings (GCS) in CLOTS Trial 1
Number of subjects: 5632
Study 21357988 — intervention group
Group type: COMPARATOR
Intervention: Below-knee graduated compression stockings (GCS) in CLOTS Trial 2
Number of subjects: 5632
Study 21357988 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on Trial 2 cohort
Number of subjects: 5632
Study 21357988 — intervention group
Group type: COMPARATOR
Intervention: Model tested in Trial 1 cohort
Number of subjects: 5632
Study 18462734 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional buccoadhesive bromocriptine methylate discs once daily for 1 month
Number of subjects: 42
Study 18462734 — intervention group
Group type: COMPARATOR
Intervention: Vaginoadhesive bromocriptine methylate discs once daily for 1 month
Number of subjects: 42
Study 16573837 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmitral Doppler flow
Number of subjects: 54
Study 16573837 — intervention group
Group type: COMPARATOR
Intervention: 2D echo
Number of subjects: 54
Study 12658365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 20
Study 12658365 — intervention group
Group type: COMPARATOR
Intervention: l-dopa
Number of subjects: 20
Study 11726036 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin (20 mg daily for 5 days before surgery)
Number of subjects: 46
Study 11726036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 46
Study 9396978 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (n = 13): encasing mattress, box springs, and pillows in allergen impermeable covers; weekly hot water wash of bed linens; replacement of bedroom carpet with polished flooring; and 3% tannic acid spray to living room carpet.
Number of subjects: 23
Study 9396978 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n = 10): permeable encasing for bedding, cold water wash, and water spray for carpet.
Number of subjects: 23
Study 9396978 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (n = 13) and Placebo treatment (n = 10)
Number of subjects: 23
Study 7609499 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual nifedipine 10 mg
Number of subjects: 40
Study 7609499 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual lacidipine 4 mg
Number of subjects: 40
Study 3280158 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (180 to 360 mg/day)
Number of subjects: 20
Study 3280158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 120 mg/day)
Number of subjects: 20
Study 3280158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Diltiazem and Nifedipine)
Number of subjects: 20
Study 3280158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31839530 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release albuterol
Number of subjects: 13
Study 31839530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30973547 — intervention group
Group type: EXPERIMENTAL
Intervention: +NENS
Number of subjects: 600
Study 30973547 — intervention group
Group type: EXPERIMENTAL
Intervention: +NS
Number of subjects: 600
Study 30973547 — intervention group
Group type: COMPARATOR
Intervention: +SE
Number of subjects: 600
Study 25553871 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system insertion within 6-48 hours after vaginal birth
Number of subjects: 35
Study 25553871 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system insertion 4-6 weeks after vaginal birth
Number of subjects: 35
Study 23613501 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF/MV ratios of 0.2, 0.3, 0.4, and 1.0 with initial FD of sevoflurane at 2.2% vol in study 1
Number of subjects: 120
Study 23613501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volumes of 6, 8, or 10 ml/kg with initial FD of sevoflurane at 2.2% vol in study 2
Number of subjects: 120
Study 21493621 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ (combined with conventional 7.5 or 8.5 mm single-lumen tube)
Number of subjects: 40
Study 21493621 — intervention group
Group type: COMPARATOR
Intervention: DLT (37 or 39 Fr left‐sided DLT)
Number of subjects: 40
Study 19306149 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent therapist contact (three e-mails per week)
Number of subjects: 57